Multiple cardioprotective signal pathways that are activated by ischaemic preconditioning (IPC) and those by IPC mimetics converge on mitochondria. Recent studies have shown that pools of Akt, protein kinase C-1, extracellular-regulated kinases, glycogen synthase kinase-3b (GSK-3b), and hexokinases (HK) I and II, are localized in mitochondria in addition to their pools in the cytosol. Accumulating evidence indicates that such 'mitochondrial protein kinases' receive signals from cytosolic molecules and enhance tolerance of myocytes to injury. Proteomic analyses suggest that these kinases form complexes with each other and with subunit proteins of the mitochondrial permeability transition pore (mPTP). Functional relationships between the protein kinases in mitochondria have not been fully clarified, but GSK-3b and HKs appear to be at the end of the signal pathways and directly responsible for inhibition of opening of the mPTP and, thus, for myocyte protection from necrosis. In this review, recent findings supporting roles of mitochondrial protein kinases in protection from myocardial necrosis after ischaemia/reperfusion are summarized and discussed.
Introduction
Mitochondria have multiple functions for cardiomyocytes to adapt to changes in extracellular and intracellular environments. Mitochondria generate ATP, buffer cytosolic Ca 2+ as Ca 2+ -storing compartments, and function as hubs of signalling pathways. Since mitochondria contain proteins that potentially execute apoptosis and necrosis, 1 -3 it is reasonable to postulate that signalling pathways of cytoprotection converge on mitochondria. In fact, a number of signalling pathways activated by ischaemic preconditioning (IPC) and other cardioprotective interventions reach mitochondria. However, when compared with sequences of protein kinase activations, intracellular locations where the kinases interact with other signalling molecules are far less clear. From results of recent studies, a complex picture of multiple signal cross-talks among mitochondria, endoplasmic reticulum, and nucleus in decision-making on death or survival of the cell has been emerging. 1 In this article, we focus on protein kinases that function in mitochondria for protection against necrosis of the myocardium. Roles of kinases in protection from apoptosis have recently been reviewed elsewhere. 1, 3 Before discussing roles of each protein kinase in protection against necrosis, we briefly review mechanisms of myocyte necrosis during ischaemia/reperfusion.
Cardiomyocyte necrosis by ischaemia and reperfusion

Metabolic derangement in cardiomyocytes during ischaemia/ reperfusion
Ischaemia reduces intracellular ATP level, elevates intracellular H + , Na + , and Ca 2+ levels, and induces osmotic loading and mitochondrial injury. After the onset of ischaemia, oxygen deficiency and damage to mitochondrial complexes I and III and cytochrome oxidase inhibit oxidative phosphorylation, and inactivation of glyceraldehyde dehydrogenase by accumulated H + and NADH inhibits anaerobic glycolysis. 4, 5 Mitochondrial ATPase consumes ATP during ischaemia to temporarily maintain mitochondrial membrane potential (Dcm). These metabolic changes are responsible for decline of ATP during myocardial ischaemia. Na + influx via the Na + -H + exchanger stimulated by intracellular H + accumulation, Na + influx via un-inactivated Na + channels, and reduction in Na + efflux via the Na + -K + pump contribute to elevation of intracellular Na + level during ischaemia. 6 -8 4 Re-supply of oxygen to mitochondria restitutes ATP production but also induces augmented production of cytotoxic reactive oxygen species (ROS) mainly from mitochondrial complexes I and III. 9,10 Ca 2+ overload and ROS production upon reperfusion are major stimuli for opening of the mitochondrial permeability transition pore (mPTP). 2 Inhibition of mPTPs or contraction of cardiomyocytes immediately after reperfusion by pharmacological inhibitors significantly limits infarct size. 11 -14 These findings support the notion that opening of the mPTP and rupture of sarcolemma by hypercontraction and oedema upon reperfusion are direct mechanisms of reperfusion-induced necrosis of cardiomyocytes.
mPTP opening and necrosis of cardiomyocytes
The mPTP is a large conductance channel in the mitochondrial inner membrane that non-selectively passes molecules ,1.5 kDa in response to its opening stimuli. Irreversible opening of mPTPs has been shown to be involved in cell necrosis by a variety of causes including ischaemia/reperfusion and anti-cancer agents. 2 However, the molecular structure of the mPTP remains unclear. An earlier model of the mPTP was a channel formed by adenine nucleotide translocase (ANT) in the inner membrane of mitochondria (IMM) and a voltage-dependent anion channel (VDAC) in the outer membrane of mitochondria (OMM 
Receptors coupled to mitochondria-mediated cytoprotection
Since the discovery of involvement of the adenosine receptor in myocardial protection afforded by IPC, knowledge of receptors relevant to cardioprotection has been expanded in the past two decades. 23 Interestingly, a variety of receptors can trigger intracellular signalling to achieve protection against infarction, including G-protein-coupled receptors (GPCRs) (adenosine A1, A3, bradykinin B2, d-opioid, angiotensin II type 1, and muscarinic M2 receptors), cytokine receptors (erythropoietin and TNF-a receptor), and receptor tyrosine kinases (EGF receptor and insulin receptor). 23 -28 Multiple signal pathways are activated by each of the receptors, and patterns of activated pathways differ depending on the type of receptor and on duration of receptor stimulation. However, several protein kinases are commonly activated by different receptors and apparently translocate to mitochondria for protection from cell necrosis. Of such 'cytoprotective mitochondrial kinases', we selected protein kinase C-1 (PKC-1), extracellular-regulated kinases (ERK), Akt, glycogen synthase kinase-3b (GSK-3b), and hexokinase (HK) for discussion in this article. Our hypothesis for their roles and relationships is shown in Figure 1 .
4. Protein kinases involved in signalling in mitochondria for myocyte protection
Akt
Akt consists of three isoforms (Akt1, Akt2, and Akt3) which have 80% homology, although each isoform is encoded by a distinct gene locus. In cardiomyocytes, Akt1 and Akt2 comprise the majority of total Akt protein. 29 Activation of receptor tyrosine kinases, cytokine receptors, or GPCRs induces production of phosphatidylinositol 3,4,5-triphosphate (PIP3) in the cell membrane via T. Miura et al.
phosphatidylinositol 3
′ -kinase (PI3K) activation, and accumulation of PIP3 leads to recruitment of Akt to the membrane, where Akt is converted to the active form by phosphoinositide-dependent protein kinase-1 (PDK1)-mediated phosphorylation at Thr308. Full activation of Akt requires the additional phosphorylation of Ser473 by a putative PDK2, but the identity of the kinase responsible remains unclear. Activated Akt is released from the plasma membrane and targets substrates in the cytosol, nucleus, and mitochondria. 28 -31 Translocation of Akt to mitochondria in response to receptor stimulation has been demonstrated in non-cardiac cells and isolated cardiomyocytes. Bijur et al. 30 first reported that stimulation of PI3K/ Akt signalling by insulin or insulin-like growth factor-1 in non-cardiac cell lines significantly increased activated Akt in mitochondrial fractions within minutes, which was maintained for 45 min. In neonatal rat ventricular myocytes, 10 min treatment with leukaemia inhibitory factor (LIF) increased levels of total and phospho-Ser473-Akt in the mitochondrial fraction. 31 Whether such a mitochondrial translocation of Akt shortly after receptor activation occurs in intact hearts has not been confirmed. It has been established that PI3K/Akt signalling plays a crucial role in anti-necrotic tolerance afforded by a variety of receptor-mediated protective interventions. Infarct size limitation by IPC and that by stimulation of cytokine receptors or GPCRs were associated with phosphorylation of Akt, and protective effects of these interventions were abrogated by PI3K inhibitors or by genetic deletion of PDK1. 23, 25, 27, 32 Conversely, overexpression of constitutively active Akt in cardiomyocytes limited infarct size after ischaemia/reperfusion. 33 Contribution of each Akt isoform to myocardial protection remains unclear, but a recent study by Cao et al. 34 indicated a sex difference in the roles of Akt isoforms. They showed that protection from necrosis by Met5-enkephalin during simulated ischaemia/reperfusion was abolished by knockdown of Akt1/2 in male myocytes and by knockdown of Akt3 in female myocytes. Akt plays dual roles in the mechanism of protection afforded by IPC and that by its mimetics: a role in the trigger phase of protection (a phase when receptor activation makes cardiomyocytes prepared for subsequent insults) and a role in the mediator phase of protection (i.e. phase when protective mechanisms suppress concurrent ischaemic and/or reperfusion injury). 23, 34 In fact, the infarct size-limiting effect of IPC is abolished by inhibition of PI3K either during IPC (i.e. before ischaemia) or at the time of reperfusion. The role of Akt in the trigger phase of IPC is likely to be played by cytosolic Akt. A series of studies by Downey et al. 23, 35, 36 indicated that activated Akt transmits a signal from PI3K to ERK/endothelial nitric oxide (eNOS)/protein kinase G (PKG) pathway, which ultimately activates the mitochondrial ATP-sensitive K + channel (mK ATP channel).
Of receptors that participate in triggering IPC mechanisms, the bradykinin B2 receptor and d-opioid receptor are coupled with this ROS-producing pathway, whereas the adenosine receptor does not require the PI3K/Akt signalling to the mK ATP channel. 23 The protective role of Akt in the mediator phase of IPC may be played in the mitochondrial compartment. IPC and its mimetics significantly enhance phosphorylation of Akt upon reperfusion, 37 -39 induce mitochondrial translocation of HK, an Akt substrate, 40 and inhibit opening of mPTPs upon reperfusion. 41, 42 Miyamoto et al. 31 showed that HKII translocated to mitochondria was phosphorylated by Akt in association with Akt translocation to mitochondria after stimulation of the LIF receptor in cardiomyocytes. Furthermore, our recent studies showed that activation of PI3K/Akt signalling by erythropoietin receptor activation induced increased interaction of Akt with ANT, a subunit of mPTP complex, and phosphorylation of GSK-3b, an Akt substrate, in the mitochondrial fraction upon reperfusion. 26 23, 46 indicating that the 1-isoform of PKC is responsible for myocyte protection.
PKC-1 appears to play cytoprotective roles in three intracellular compartments, the cytosol, sarcolemma, and mitochondria. Cytosolic targets of PKC-1 for cytoprotection are Akt and eNOS. Zhang et al. 47 showed that constitutively active PKC-1 forms a signalling module with Akt and eNOS. Interestingly, activity of Akt and eNOS in the signalling module was enhanced by PKC-1-mediated phosphorylation. Although the precise role of this PKC-1-Akt -eNOS complex in cardiomyocyte protection is not clear, it is plausible that Akt/ERK/eNOS/ PKG signalling to the mK ATP channel in the trigger phase of IPC (or protection of its mimetics) is enhanced by the PKC-1-mediated activation of Akt and eNOS.
A target of activated PKC-1 in the sarcolemma is the adenosine A2b receptor. Studies by Kuno et al. 39, 48 showed that activation of PKC significantly sensitized the A2b receptor to adenosine and that enhanced activation of PI3K/Akt-and ERK-mediated signalling upon reperfusion in the preconditioned myocardium was abrogated either by A2b receptor blockers or by a PKC inhibitor. Since PI3K/ Akt-and ERK-mediated signalling needs to be highly activated upon reperfusion to protect hearts from lethal reperfusion injury, 37 sensitization of the A2b receptor by PKC-1 is critical for IPC protection.
In mitochondria, PKC-1 forms a complex with mitogen-activated protein kinases (i.e. ERKs, JNKs, and p38MAPK) and components of mPTPs (i.e. VDAC, ANT, and HKII). 49, 50 Furthermore, ERKs were highly phosphorylated and binding of PKC-1 to VDAC1, ANT1, and HKII was enhanced in mitochondria of mice overexpressing active PKC-1. GST-pull-down experiments in vitro showed that VDAC1, but not ANT or HKII, is a direct binding partner with PKC-1.
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ERKs localize in the intermembrane space (IMS) of mitochondria and ERK phosphorylation was shown to inhibit mPTP opening via GSK-3b phosphorylation in non-cardiac cells as discussed in Section 4.3. 51 In active PKC-1 overexpressed mouse hearts, the threshold for mPTP opening in response to Ca 2+ overloading was significantly elevated. 50 Taken together, these findings suggest that activated PKC-1 in the IMS inhibits mPTP opening by ERK -GSK-3b signalling. Localization of PKC-1 in the IMS was also hypothesized by Garlid and his colleagues, but they postulated a second pool of PKC-1 in the matrix side of the IMM. In experiments using mitochondria swelling as an index of mK ATP channel activation, they showed that a PKC-1-specific activator (c1RACK) and non-specific activators [H 2 O 2 , NO donor, and phorbol-12-myristate-13-acetate (PMA)] activate the mK ATP channel.
52 1V1-2, a small PKC-1 inhibitory peptide, abrogated effects of the PKC-1 activators on the mK ATP channel. In contrast, inhibition of mPTP was achieved by H 2 O 2 , NO donor, and PMA but not by c1RACK, although 1V1-2 abrogated mPTP inhibition by PKC activators. c1RACK is an anionic peptide that would not enter the mitochondrial matrix. On the basis of these findings, they proposed that a pool of PKC-1 in the IMS regulates the mK ATP in the IMM and that a pool of PKC-1 facing the matrix side of the IMM directly participates in mPTP inhibition. ERK is also involved in regulation of the mK ATP channel, but its role is phosphorylation of eNOS, which leads to activation of PKG, a putative terminal cytosolic factor in signalling to the mK ATP channel. 36, 53 In other words, ERKs regulating the mK ATP channel localize in the cytosol. Mitochondrial aldehyde dehydrogenase-2, which oxidizes cytotoxic aldehydes to carboxylic acids, was recently found to be an important target of activated PKC-1 for affording cytoprotection. The role of this dehydrogenase in cardioprotection is extensively discussed by Mochly-Rosen et al.
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PKC-1 may be involved in attenuation of ATP hydrolysis during ischaemia by IPC. The slowed decline of tissue ATP level after the onset of ischaemia is a metabolic hallmark of preconditioned myocardium, and it is attributable to reduced ATP utilization. As in preconditioned hearts, in hearts expressing constitutively active PKC-1, depletion of tissue ATP level during ischaemia was significantly delayed compared with that in non-transgenic controls, although heart rates and rate-pressure products were similar under baseline conditions. 55 Interestingly, mitochondria were hyperpolarized in PKC-1-overexpressed hearts, 56 although it is not clear whether mitochondrial or extra-mitochondrial PKC-1 is responsible for the difference. During ischaemia, ATP is hydrolysed mainly by mitochondrial ATPase, 4 which depends on the level of Dcm. 57 Thus, there is a possibility that attenuated depolarization of Dcm underlies PKC-1-mediated reduction of ATP consumption during ischaemia. Nevertheless, since depletion of ATP and elevation of the level of inorganic phosphate are stimuli for mPTP opening, PKC-1-mediated suppression of ATP hydrolysis during ischaemia potentially attenuates priming of the mPTP before reperfusion. Sex difference in PKC-1 level in mitochondria appears to be responsible for higher tolerance of female hearts to ischaemia/ reperfusion injury than that of male hearts. Lagranha et al. 58 found that mitochondrial PKC-1 level was two-fold higher in female rat hearts than in male hearts and that two PKC-regulated proteins, ALDH2 and a-ketoglutarate dehydrogenase (a-KGDH), were significantly more phosphorylated in the female. These features in female hearts were eliminated by ovariectomy or by inhibition of PI3K. Level of ROS production during simulated ischaemia was significantly lower in female myocytes than in male myocytes. These findings suggest that mitochondrial PKC-1 up-regulated by oestrogen receptor/PI3K signalling protects cardiomyocytes by two mechanisms, suppression of ROS generation by a-KGDH and detoxification of ROS-generated aldehydes by ALDH2 in female hearts.
In contrast to PKC-1, activation and translocation of PKC-d to mitochondria by ischaemia/reperfusion is rather detrimental to cardiomyocyte survival. Translocation of PKC-d to mitochondria is associated with tricarboxylic acid cycle activity, reduction in mitochondrial respiration, and augmentation of ROS production. 59, 60 Inhibition of PKC-d activity at the time of reperfusion by a PKC-d-specific inhibitory peptide reduced infarct size in swine and rat models of myocardial infarction. 61, 62 Interestingly, protein level of PKC-d in mitochondria is regulated by PKC-1. Overexpression of dominant-negative PKC-1 induced translocation of PKC-d to mitochondria and its phosphorylation at Thr505 in non-ischaemic mouse hearts. 63 Conversely, activation of PKC-1 by IPC reduced mitochondrial PKC-d level after ischaemia/reperfusion by proteasome-mediated degradation of PKC-d. 64 On the other hand, transient activation of PKC-d before ischaemia has been shown to indirectly induce PKC-1 activation via stimulation of adenosine receptors. 65 These findings indicate that functions of PKC-d and PKC-1, two kinases playing opposing roles in cell survival, are mutually regulated in cardiomyocytes.
Extracellular-regulated kinases
ERK1 and ERK2 are activated after stimulation of receptor tyrosine kinases/cytokine receptors or GPCRs. 66 Activation of receptor tyrokine kinases or adaptor proteins with tyrosine kinase activity induces sequential activation of Ras, Raf, MEK1/2, and ERK1/2. PKC and protein kinase A (PKA) downstream of GPCRs also activate Raf, leading to MEK/ERK signalling. Activated ERK1/2 stays in the cytosol or translocates to the nucleus and other intracellular compartments. Localization of ERKs in mitochondria has been confirmed in cardiac and non-cardiac cells. Baines et al. 49 found that ERK1/2 as well as JNK and p38MAPK were co-immunoprecipitated with PKC-1 in murine cardiomyocyte mitochondria. Kinase activity of PKC-1 was unnecessary for this physical interaction of PKC-1 with MAPKs, but phosphorylation of ERK was observed in complex with a constitutively active PKC-1 mutant but not in that with inactive PKC-1. Localization of ERKs within mitochondria and kinetics of their activation have been characterized in more detail in non-cardiac cells. In P07 tumour cells, ERK level in mitochondria was low, but a low dose of H 2 O 2 induced translocation of ERK1/2 to mitochondria and nuclei, and the level of phosphorylated ERK2 was increased more than three-fold in mitochondria. 67 Experiments using submitochondrial fractionation and immunoblotting indicated that ERK1/2 and MEK1/2 localize in the IMS and OMM, consistent with findings by immuno-electron microscopy.
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A study by Dagda et al. 68 showed that co-localization of ERK2 with mitochondria was kinase activity-dependent. In their experiments using SH-SY5Y cells, green fluorescent protein (GFP)-labelled ERK2 was co-localized with mitochondria stained with MitoTracker Red after activation of ERK by 6-hydroxydopamin. GFP-labelled constitutively active ERK2 was localized in mitochondria, whereas such co-localization with mitochondria was not detected for kinasedeficient ERK2. Several lines of evidence support the notion that mitochondrial ERK contributes to inhibition of mPTP opening at the time of reperfusion. An inhibitor of MEK1, PD98059, abolished elevation of the threshold for mPTP opening by activation of the GPCR 30 in cardiomyocytes. 72 Recently, Rasola et al. 51 found that cancer cell lines resistant to necrosis (RWPE-2, DU145, and SAOS-2) have constitutively active ERK in mitochondria. The threshold for mPTP opening was significantly higher in RWPE-2 cells than in controls lacking active ERK in mitochondria, and this difference was eliminated by treatment with PD98059. Furthermore, Ser9-phosphorylation of GSK-3b in mitochondria after overnight fasting was suppressed by inhibiting ERK in SAOS-2 cells. These findings indicate that mitochondrial GSK-3b is one possible target for mitochondrial ERK to inhibit mPTP opening and thus cell necrosis.
Glycogen synthase kinase-3b
There are two GSK-3 isoforms, GSK-3a and GSK-3b, which are highly homologous but substantially differ in functions. GSK-3b is ubiquitously expressed and phosphorylates more than 30 substrates besides glycogen synthase. GSK-3b is constitutively active and its function is regulated by phosphorylation at Ser9 and Tyr216, by translocation to intracellular compartments, by priming phosphorylation of substrates, and by binding to scaffold proteins in kinase-substrate interaction. 73 Phosphorylation at Ser9 reduces GSK-3b activity and, conversely, phosphorylation at Tyr216 increases its activity. Akt, PKA, PKC, PKG, and ERK phosphorylate GSK-3b at Ser9 and thus multiple classes of receptors potentially participate in regulation of GSK-3b activity. Phosphorylation of GSK-3b at Tyr216 is induced by autophosphorylation, although the possibility of involvement of tyrosine kinases in the tyrosine phosphorylation cannot be excluded. 74 In cardiomyocytes, both immunoblotting for GSK-3b
and immunohistochemical methods showed that GSK-3b mainly localizes in the cytosol under physiological conditions.
26,75
Tong et al. 76 first reported a role of GSK-3b in regulation of myocardial vulnerability to ischaemia/reperfusion-induced necrosis. They found that IPC induced inhibitory phosphorylation of GSK-3b at Ser9 in isolated rat hearts and that a pharmacological blocker of GSK-3, SB216763, mimicked the infarct size-limiting effect of IPC. Such an association of GSK-3b phosphorylation and infarct size limitation was observed for pre-ischaemic treatments with opioids, erythropoietin and isoflurane. 24 Furthermore, structurally different inhibitors of GSK-3 (SB216763, BIO, lithium chloride) consistently limited infarct size in rat and rabbit hearts not only when used for pre-ischaemic treatment but also when administered shortly before reperfusion. 76 -78 On the other hand, expression of phosphorylation-insensitive GSK-3b (GSK-3b-S9A) in transgenic mice made their hearts refractory to IPost-induced protection. Furthermore, we found that there was a close negative correlation between tissue levels of phospho-GSK-3b at 5 min after reperfusion and infarct sizes after 2 h reperfusion in rat hearts in vivo. 25 Taken together, these findings indicate that GSK-3b activity is a determinant of myocardial vulnerability to reperfusion-induced necrosis. Target proteins of GSK-3b relevant to cell death (i.e. p53, heat shock factor-1, myeloid cell leukaemia sequence-1, Bax and Bcl-2, VDAC, and ANT) are distributed in both the cytosol and mitochondria. 24 Thus, GSK-3b in both compartments appears to potentially contribute to cell apoptosis and necrosis. However, several lines of evidence support the notion that mitochondrial GSK-3b plays a predominant role in myocyte necrosis after ischaemia/reperfusion injury. First, Juhaszova et al. 79 demonstrated that the threshold for mPTP opening in response to ROS was significantly attenuated by inactivation of GSK-3b or knockdown of GSK-3b expression in cardiomyocytes. Secondly, our study showed that GSK-3b translocates to mitochondria and physically interacts with ANT and VDAC, mPTP subunits, after ischaemia/reperfusion. 26 Furthermore, GSK-3b phosphorylated by IPC and erythropoietin receptor activation was found to be binding to ANT, but not to VDAC, and protein level of phosho-GSK-3b-ANT complex was reduced by a PKC inhibitor or a PI3K inhibitor. 26 It is unlikely that phosphorylation of GSK-3b at Ser9 and mitochondrial translocation are causally related since the level of co-localization of GFP-tagged GSK-3b with mitochondria was unchanged when the level of phospho-GSK-3b was increased by almost 50% after erythropoietin receptor activation. 75 Thirdly, we found that there was a significant correlation between the thresholds for mPTP opening in isolated cardiac mitochondria and ratio of phospho-GSK-3b to total GSK-3b in the mitochondrial samples. 77 Fourthly, phosphorylation of VDAC by GSK-3b was shown to facilitate ATP transport to the mitochondrial matrix via VDAC, which accelerates ATP depletion during ischaemia. 80 Together with the results of a study by Rasola et al. 51 discussed in Section 4.3, these findings suggest that inactivation of mitochondrial GSK-3b by ERK, Akt, and PKC increases the threshold for mPTP opening and thus tolerance to ischaemia/reperfusion injury. The mechanism by which inactivation of GSK-3b increases the threshold for mPTP opening is still unclear, but there are several possibilities. 24 First, inhibition of GSK-3b-mediated phosphorylation of VDAC may reduce both transport of cytosolic ATP to the mitochondrial matrix and release of HKII from mitochondria. Secondly, enhancement of p53 activity by GSK-3b and thus p53-mediated stimulation of mPTP opening may be attenuated by inactivation of GSK-3b. 81 Thirdly, sensitization of mPTPs by CypD may be attenuated by interaction of ANT, a binding partner of CypD, with phospho-GSK-3b. 26 It is notable that not only receptor agonists but also pharmacological inhibitors of GSK-3b increase phospho-GSK-3b level since GSK-3b activity positively regulates protein phosphatase-1 being responsible for GSK-3b dephosphorylation. 82 
Hexokinase
There are four isoforms of HK which differ in affinities for glucose and sensitivities to inhibition by glucose-6-phosphate (G6P). 83 In cardiomyocytes, HKI and HKII localize in both the cytosol and mitochondria, and a hydrophobic N-terminal domain of these HKs is responsible for both their binding to the OMM and physical interaction with VDAC. 84 Phosphorylation of glucose by HKs to G6P maintains free glucose in the cytosol at low level, facilitating glucose uptake via glucose transporters. In mitochondria, HKs bound to VDAC play a role in maintaining Dcm by supply of ADP to the mitochondrial matrix. VDAC forms a complex with ANT, and ADP produced as a result of glucose phosphorylation by HK is transported via ANT to the mitochondrial matrix and used for ATP production by ATP synthase. Sensitivity of HKs to end-product inhibition by G6P is markedly reduced by binding to the mitochondria, 85, 86 which improves efficiency of ADP transport into the mitochondrial matrix.
Another possible function of mitochondria-bound HKs is locking a trigger mechanism of apoptosis. Different interventions that induce detachment of HKs from mitochondria consistently induce cell apoptosis. Although the precise mechanism of this phenomenon is unclear, it is suggested that HK binding to VDAC spares Bcl-XL, an antiapoptotic Bcl-2 family protein, which can bind to VDAC, for interaction with pro-apoptotic proteins such as Bax and Bak. 87 Involvement of mitochondrial HKs in regulation of the mPTP has been demonstrated in non-cardiac cells and cardiomyocytes. Chiara et al. 88 showed that the threshold for mPTP opening in response to repetitive Ca 2+ challenge was significantly reduced by TAT-HK, a cellpermeable N-terminal hydrophobic domain of HK, which induces detachment of HKs from mitochondria, in HeLa cells. TAT-HK induced dose-dependent cell death, and this effect of TAT-HK was abrogated by a CypD inhibitor, Debio 025, confirming involvement of mPTPs. Conversely, increase in the threshold for mPTP opening by recruitment of HKs to mitochondria was observed by Sun et al. 89 They showed that transfection of HKI or HKII significantly attenuated opening of mPTPs and cell death during hydrogen peroxide challenge in neonatal rat cardiomyocytes. Furthermore, the effects on mPTP threshold and cell death were partially lost by deletion of the N-terminal domains required for binding to mitochondria. However, the molecular mechanism by which detachment of HKII from mitochondria facilitates mPTP opening is unclear. Recent studies have indicated that GSK-3b and Akt are involved in HK binding to mitochondria. 90 -93 In HeLa cells, enhanced GSK-3b activity by inhibition of Akt was associated with phosphorylation of VDAC and release of HKII from mitochondria. 90 Chronic inhibition of GSK-3b increased the level of HKII co-localized with mitochondria by 20% in neuronal cells, although translocation of HKII was not immediately induced after GSK-3b inhibition. 91 In contrast with GSK-3b, activation of Akt promotes translocation of HKII to mitochondria. 31, 92, 93 In studies by Majewski et al., 92, 93 transfection of constitutively active Akt and treatment with insulin significantly increased mitochondrial HK activity in non-cardiac cells. Such an increase in HK activity after insulin treatment was inhibited by LY294002, a PI3K inhibitor, and was not detected in cells from Akt knock-out mice. Similarly, in cardiomyocytes, activation of the LIF receptor induced translocation of both Akt and HKII to mitochondria in an LY294002-sensitive manner. 31 Since IPC and its mimetics activate PI3K/Akt signalling and inactivate GSK-3b by phosphorylation, they are expected to increase HK levels in the mitochondria. That was indeed the case in rat hearts. 40, 94 Zuurbier et al. 40 showed that IPC, infusion of insulin, and infusion of morphine similarly increased HK activity in the mitochondrial fraction by 30%, whereas HK activity in the cytosolic fraction was reduced by 20%. By the use of immuno-electron microscopy, Southworth et al. 94 confirmed insulin-induced translocation of HKI and HKII to mitochondria in the myocardium. Together with findings on modification of the mPTP by HK in non-cardiac cells, these findings support the hypothesis that increased HK binding to mitochondria by PI3K/Akt/GSK-3b signalling is a mechanism of myocardial protection against infarction.
Observations defying roles of mitochondrial protein kinases in cardioprotection
It should be noted that not all studies support a significant contribution of 'mitochondrial kinases' to myocardial protection from infarction. Clarke et al. 95 purified mitochondrial fractions from rat hearts using the Percoll gradient technique and assessed effects of IPC on mitochondrial proteins. They found no effects of IPC on phosphorylation of mitochondrial PKCs, GSK-3b, or Akt, although protein carbonylation after ischaemia/reperfusion was significantly suppressed by IPC. Skyschally et al. 96 showed that the combination of ERK and PI3K inhibitors administered before reperfusion did not abolish infarct size limitation by IPost in swine hearts and that levels of ERK, Akt, and GSK-3b phosphorylation were not correlated with the extent of myocardial protection. In a study by Nishino et al., 97 protection afforded by IPC and that by IPost were preserved in GSK-3a/b knock-in mice in which Ser21 of GSK-3a and Ser9 of GSK-3b were changed to Ala. Surprisingly, pharmacological inhibitors of GSK-3b failed to limit infarct size in these knock-in mice and also in wild-type controls. These observations are difficult to reconcile with results of studies discussed in preceding sections. Differences in methods of mitochondrial isolation leading to analysis of different groups of mitochondria and differences in roles of mitochondrial kinases depending on experimental conditions and/or animal species are possible explanations for the contradictions, although these possibilities remain to be critically examined.
Conclusion
Accumulating evidence indicates that several protein kinases (i.e. Akt, PKC-1, ERK, GSK-3b, and HK) receive extra-mitochondrial signals and modify mitochondrial proteins determining death/survival of the cell such as the mPTP. Activities of some of these kinases are mutually regulated, and phosphorylation of GSK-3b and HK in mitochondria appears to directly modify the mPTP to elevate its threshold for opening. However, the molecular structure of the mPTP and its modification by GSK-3b and HK remain unclear. Furthermore, recent studies have suggested that there are modifications by concurrent diseases in signalling pathways of mitochondrial protein kinases. 77 -79,98 For example, we found that ERK-GSK-3b signalling is lost by increased endoplasmic reticulum stress in the diabetic myocardium. 77, 79 This issue needs to be further investigated for translation of data from bench to bedside.
